The subcutaneous implantable cardioverter–defibrillator (ICD) is associated with fewer lead-related complications than a transvenous ICD; however, the subcutaneous ICD cannot provide bradycardia and ...

Cardiac device therapy has significantly evolved since the introduction of the first implantable pacemaker and the subsequent ...

The Subcutaneous Implantable Cardioverter‑Defibrillator System Post Approval Study (S‑ICD PAS), which observed patients with subcutaneous implantable cardioverter-defibrillators (S‑ICDs) for 5 years, ...

BOSTON -- A leadless pacemaker reliably communicated with a subcutaneous implantable cardioverter-defibrillator (S-ICD) to deliver anti-tachycardia (ATP) and bradycardia pacing, the MODULAR ATP study ...

First-of-its-kind Aurora EV-ICD™ system offers single device, single procedure with lead placed outside of heart and veins FDA approval of the Medtronic Aurora EV-ICD system includes the system's ...

SAN DIEGO, CA—Use of a subcutaneous implantable cardioverter-defibrillator (S-ICD) appears to have some advantages over transvenous devices for patients with an ICD indication but no need for pacing, ...

EV-ICD defibrillation lead placed outside of heart and veins, preserving vasculature Patients implanted with the Aurora EV-ICD system have defibrillation, anti-tachycardia pacing (ATP), and back-up ...

A new type of extravascular implantable cardioverter-defibrillator (ICD) using a lead (thin wire) placed behind the sternum met safety and effectiveness goals for participants in a premarket global ...

The US Food and Drug Administration has approved Medtronic's novel "extravascular" implantable cardioverter-defibrillator (Aurora EV-ICD) system, which uses a single lead implanted substernally to ...

Harish Manyam, MD, is on a mission to improve the lives of people with heart problems. His recent accomplishment of implanting Tennessee’s first atrial leadless pacemaker is a step toward that, ...